Zusammenfassung
In den Jahren 2018 und 2020 haben zwei Metaanalysen zu kumulativen Ergebnissen von randomisierten und kontrollierten Studien eine erhöhte Sterblichkeit nach der Anwendung Paclitaxel-beschichteter Stents bzw. Ballons in den Gefäßen der unteren Extremitäten berichtet. Im Anschluss daran entwickelte sich eine angeregte globale Diskussion über die Validität dieser Assoziation, wobei die Ergebnisse zahlreicher Beobachtungsstudien mit klinischen und administrativen Registerdaten die Anwendungssicherheit beschichteter Medizinprodukte nahelegten. Dieser Artikel fasst die Entwicklung und Verbreitung Paclitaxel-beschichteter Ballons und Stents zur Behandlung der peripheren arteriellen Verschlusskrankheit in der klinischen Praxis, in Studien und in Leitlinien zusammen. Hierbei wird ein besonderer Fokus auf die neue Medizinprodukteregulation der Europäischen Union gelegt, die weitreichende Implikationen für die Marktzulassung und Überwachung von Hochrisikomedizinprodukten hat.
Abstract
In 2018 and 2020, two meta-analyses using summary-level data from randomized controlled trials reported worse mortality following the application of paclitaxel-coated stents and balloons in femoropopliteal and crural arteries. These results initiated a heated global discussion concerning the validity of this association, while various observational studies using clinical and administrative registries proved the safety of coated devices. This article aimed to summarize the development and adoption of paclitaxel-coated balloons and stents for the treatment of peripheral arterial occlusive disease in clinical practice, research, and practice guidelines. It especially focusses on the European Unionʼs medical device regulation, which has far-reaching implications for the market approval and monitoring of high-risk medical devices.
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs00772-020-00713-5/MediaObjects/772_2020_713_Fig1_HTML.png)
Literatur
Aboyans V, Ricco JB, Bartelink MEL et al (2018) Editor’s choice – 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg 55:305–368
Anonymous (2019) Correction to: Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery 5‑year results of the Zilver PTX randomized trial. Circulation 139:e42
Lawall et al (2016) S3-Leitlinie PAVK – Diagnostik, Therapie und Nachsorge der peripheren arteriellen Verschlusskrankheit. Vasa 45(Suppl 95):1–100
Behrendt CA, Peters F, Mani K (2020) The swinging pendulum of evidence: Is there a reality behind results from randomised trials and real world data? Lessons learned from the paclitaxel debate. Eur J Vasc Endovasc Surg 59:510–511
Behrendt CA, Sedrakyan A, Peters F et al (2020) Editor’s choice—Long term survival after femoropopliteal artery revascularisation with paclitaxel coated devices: a propensity score matched cohort analysis. Eur J Vasc Endovasc Surg 59:587–596
Behrendt CA, Sigvant B, Kuchenbecker J et al (2020) International variations and gender disparities in the treatment of peripheral arterial occlusive disease—a report from VASCUNET and the International Consortium of Vascular Registries. Eur J Vasc Endovasc Surg. https://doi.org/10.1016/j.ejvs.2020.08.027
Bertges DJ, Sedrakyan A, Sun T et al (2020) Mortality after paclitaxel coated balloon angioplasty and stenting of superficial femoral and popliteal artery in the vascular quality initiative. Circ Cardiovasc Interv 13:e8528
Böhme T, Noory E, Beschorner U et al (In Press) Evaluation of mortality following paclitaxel drug-coated balloon angioplasty of femoropopliteal lesions in patients with ulcerations and gangrene—a single center experience. Vasa
Columbo JA, Martinez-Camblor P, Mackenzie TA et al (2018) Comparing long-term mortality after carotid endarterectomy vs carotid stenting using a novel instrumental variable method for risk adjustment in observational time-to-event data. JAMA Netw Open 1:e181676
Conte MS, Bradbury AW, Kolh P et al (2019) Global vascular guidelines on the management of chronic limb-threatening ischemia. Eur J Vasc Endovasc Surg 58:S1–S109.e133
Dake MD, Ansel GM, Jaff MR et al (2016) Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery: 5‑year results of the Zilver PTX randomized trial. Circulation 133:1472–1483 (discussion 1483)
Dinh K, Gomes ML, Thomas SD et al (2020) Mortality after paclitaxel-coated device use in patients with chronic limb-threatening ischemia: a systematic review and meta-analysis of randomized controlled trials. J Endovasc Ther 27:175–185
Feldman DN, Armstrong EJ, Aronow HD et al (2018) SCAI consensus guidelines for device selection in femoral-popliteal arterial interventions. Catheter Cardiovasc Interv 92:124–140
Frank U, Nikol S, Belch J et al (2019) ESVM guideline on peripheral arterial disease. Vasa 48:1–79
Gerhard-Herman MD, Gornik HL, Barrett C et al (2017) 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol 69:e71–e126
Grube E, Schofer J, Hauptmann KE et al (2010) A novel paclitaxel-eluting stent with an ultrathin abluminal biodegradable polymer. JACC Cardiovasc Interv 3:431–438
Heidemann F, Peters F, Kuchenbecker J et al (2020) Long term outcomes after revascularisations below the knee with paclitaxel coated devices: a propensity score matched cohort analysis. Eur J Vasc Endovasc Surg. https://doi.org/10.1016/j.ejvs.2020.06.033
Katsanos K, Spiliopoulos S, Kitrou P et al (2018) Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc 7:e11245
Katsanos K, Spiliopoulos S, Kitrou P et al (2020) Risk of death and amputation with use of paclitaxel-coated balloons in the infrapopliteal arteries for treatment of critical limb ischemia: a systematic review and meta-analysis of randomized controlled trials. J Vasc Interv Radiol 31:202–212
Krawisz A, Secemsky EA (2019) Real-world data collection regarding paclitaxel treatment. Endovasc Today 18:72–76
Kreutzburg T, Peters F, Riess HC et al (2020) Editor’s choice—Comorbidity patterns among patients with peripheral arterial occlusive disease in Germany: a trend analysis of health insurance claims data. Eur J Vasc Endovasc Surg 59:59–66
Kuno T, Ueyama H, Mikami T et al (2020) Mortality in patients undergoing revascularization with paclitaxel eluting devices for infrainguinal peripheral artery disease: insights from a network meta-analysis of randomized trials. Catheter Cardiovasc Interv. https://doi.org/10.1002/ccd.29125
Lansky AJ, Costa RA, Mintz GS et al (2004) Non-polymer-based paclitaxel-coated coronary stents for the treatment of patients with de novo coronary lesions. Circulation 109:1948–1954
Liistro F, Porto I, Angioli P et al (2013) Drug-eluting balloon in peripheral intervention for below the knee angioplasty evaluation (DEBATE-BTK): a randomized trial in diabetic patients with critical limb ischemia. Circulation 128:615–621
Mills JL, Conte MS, Murad MH (2019) Critical review and evidence implications of paclitaxel drug-eluting balloons and stents in peripheral artery disease. J Vasc Surg 70:3–7
Mohapatra A, Bertges DJ, Madigan MC et al (2018) Nationwide trends in drug-coated balloon and drug-eluting stent utilization in the femoropopliteal arteries. J Vasc Surg 68:e15–e16
Moliterno DJ (2005) Healing Achilles—sirolimus versus paclitaxel. N Engl J Med 353:724–727
Mustapha JA, Brodmann M, Geraghty PJ et al (2019) Drug-coated vs uncoated percutaneous transluminal angioplasty in infrapopliteal arteries: six-month results of the Lutonix BTK trial. J Invasive Cardiol 31:205–211
Ouriel K, Adelman MA, Rosenfield K et al (2019) Safety of paclitaxel-coated balloon angioplasty for femoropopliteal peripheral artery disease. JACC Cardiovasc Interv 12:2515–2524
Peters F, Kreutzburg T, Kuchenbecker J et al (2020) Behandlungsqualität in der operativ-interventionellen Gefäßmedizin – was können Routinedaten der Krankenkassen leisten? Gefässchirurgie. https://doi.org/10.1007/s00772-020-00664-x
Rissanen TT, Uskela S, Eränen J et al (2019) Drug-coated balloon for treatment of de-novo coronary artery lesions in patients with high bleeding risk (DEBUT): a single-blind, randomised, non-inferiority trial. Lancet 394:230–239
Rocha-Singh KJ, Duval S, Jaff MR et al (2020) Mortality and paclitaxel-coated devices. Circulation 141:1859–1869
Saratzis A, Lea T, Yap T et al (2020) Paclitaxel and mortality following peripheral angioplasty: an adjusted and case matched multicentre analysis. Eur J Vasc Endovasc Surg 60:220–229
Scheller B, Hehrlein C, Bocksch W et al (2006) Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med 355:2113–2124
Schneider PA, Laird JR, Doros G et al (2019) Mortality not correlated with paclitaxel exposure: an independent patient-level meta-analysis of a drug-coated balloon. J Am Coll Cardiol 73:2550–2563
Schneider PA, Laird JR, Tepe G et al (2018) Treatment effect of drug-coated balloons is durable to 3 years in the femoropopliteal arteries: long-term results of the IN.PACT SFA randomized trial. Circ Cardiovasc Interv 11:e5891
Secemsky EA, Kundi H, Weinberg I et al (2019) Association of survival with femoropopliteal artery revascularization with drug-coated devices. JAMA Cardiol 4:332–340
Sedrakyan A, Campbell B, Merino JG et al (2016) IDEAL-D: a rational framework for evaluating and regulating the use of medical devices. BMJ 353:i2372
Tepe G, Schnorr B, Albrecht T et al (2015) Angioplasty of femoral-popliteal arteries with drug-coated balloons: 5‑year follow-up of the THUNDER trial. JACC Cardiovasc Interv 8:102–108
Zhang X, **e J, Li G, Chen Q, Xu B (2014) Head-to-head comparison of sirolimus-eluting stents versus paclitaxel-eluting stents in patients undergoing percutaneous coronary intervention: a meta-analysis of 76 studies. PLoS One. https://doi.org/10.1371/journal.pone.0097934
Yang C‑P, Horwitz S (2017) Taxol®: the first microtubule stabilizing agent. Int J Mol Sci 18(8):1733
Zeller T, Baumgartner I, Scheinert D et al (2014) Drug-eluting balloon versus standard balloon angioplasty for infrapopliteal arterial revascularization in critical limb ischemia: 12-month results from the IN.PACT DEEP randomized trial. J Am Coll Cardiol 64:1568–1576
Zeller T, Beschorner U, Pilger E et al (2015) Paclitaxel-coated balloon in infrapopliteal arteries: 12-month results from the BIOLUX P‑II randomized trial (BIOTRONIK’S-first in man study of the Passeo-18 LUX drug releasing PTA balloon catheter vs. the uncoated Passeo-18 PTA balloon catheter in subjects requiring revascularization of infrapopliteal arteries). JACC Cardiovasc Interv 8:1614–1622
Zeller T, Noory E, Beschorner U et al (2019) Outstanding effectiveness of paclitaxel-based technologies for the treatment of femoropopliteal artery occlusive disease on the potential expense of increased late all-cause mortality? No reason to panic. Vasa 48:109–111
Funding
Diese Arbeit ist durch Mittel der RABATT-Studie gefördert worden (Innovationsfonds des Gemeinsamen Bundesausschusses, Förderkennzeichen 01VSF18035, PI: CAB).
Author information
Authors and Affiliations
Consortia
Corresponding author
Ethics declarations
Interessenkonflikt
C.-A. Behrendt ist Vorsitzender des Medical Device Epidemiology Network (MDEpiNet) Verband Deutschland e. V. i.G. und beratend tätig im wissenschaftlichen Beirat einer akkreditierten benannten Stelle (MEDCERT). U. Rother, G. Rümenapf, C. Uhl, H. Görtz und D. Böckler geben an, dass kein Interessenkonflikt besteht.
Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.
Rights and permissions
About this article
Cite this article
Behrendt, CA., Rother, U., Rümenapf, G. et al. Randomisierte kontrollierte Studien und Real-World-Evidence in der Marktzulassung und Überwachung von Hochrisikoprodukten – Das Beispiel Paclitaxel. Gefässchirurgie 26, 110–117 (2021). https://doi.org/10.1007/s00772-020-00713-5
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00772-020-00713-5